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Angiotensin receptors in glomeruli differ from those in renal
arterioles. Angiotensin receptors in afferent and efferent arter-
ioles and in the glomerulus are strategically located to influence
renal perfusion and glomerular function. With the size of isolated
glomeruli as the index, we have demonstrated identical dose-
response relationships for graded concentrations (10_13 to l0-
g/liter) of angiotensin II (All) and angiotensin III (AIlI). An
octapeptide analogue (saralasin l0 to l0_2 g/liter) was equally
effective at blocking glomerular responses to both All and Alli,
but two heptapeptide analogues (des-asp,8-ile All and des-asp,8-
gly All; l0 to 10_2 g/liter) failed to block responses to either
agonist. The relative influence of octapeptide and heptapeptide
analogues on GFR was examined in anesthetized dogs with
partial occlusion of the thoracic inferior vena cava. In 18 dogs,
caval occlusion reduced renal blood flow (35%), GFR (29%), and
arterial pressure (13%). Saralasin (300 to 3000 ng/kg/min, i.v.)
and des-asp,8-ile All (100 to 3000 ng/kg/min, i.v.) increased renal
blood flow by 0.41 0.11 and 0.62 0.11 mllglmin, respective-
ly, but only the octapeptide induced a concomitant increase in
GFR (octapeptide: LGFR = 0.11 0.03 ml/g/min; heptapeptide:
LGFR = —0.08 0.07 ml/glmin; P < 0.025). As octapeptide
and heptapeptide analogues were equally effective on renal blood
flow in this and in previous studies, but only the octapeptide was
effective in isolated glomeruli and in increasing GFR in the intact
animal, we conclude that renal vascular and glomerular recep-
tors differ. Furthermore, the glomerular receptor may be the
more important in modulating the glomerular functional response
to angiotensin.
Les récepteurs glomerulaires de l'angiotensine sont différents de
ceux des arterioles rénales. Les récepteurs de l'angiotensine dans
les arterioles afférentes et efférentes et dans le glomerule sont
localisés de facon a influer sur Ia perfusion rénale et Ia fonction
glomCrulaire. En utilisant Ia taille de glomérules isolés comme
index nous avons mis en evidence des relations dose-response
identiques pour des concentrations croissantes (l0' to iO
g/litre) d'angiotensine 11 (All) et d'angiotensine III (Alli). Un
octapeptide analogue (saralasine l0 to 10_2 g/litre) est aussi
efficace dans le blocage des réponses glomerulaires a l'angioten-
sine II qu'à l'AIII, mais deux heptapeptides analogues (des-
asp,8-ile All et des-asp,8-gly All; 10 to l0_2 g/litre) ne bloquent
pas les répônses a ces agonistes. Les influences relatives des
analogues octapeptide et heptapeptide sur le GFR ont été
étudiCes chez le chien anesthésié au cours d'une occlusion
partielle de Ia veine cave inférieure thoracique. Chez 18 chiens
l'occlusion cave a diminué le debit sanguin renal (35%), Ic GFR
(29%) et Ia pression artérielle (13%). La saralasine (300 to 3000
ng/kg/min, i.v.) et la des-asp,8-ile All (100-3000 ng/kg/min) ont
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augmenté Ic debit sanguin renal de 0,41 0,11 et 0,62 0,11
ml/g/min, respectivement, mais seul l'octapeptide a déterminé
une augmentation concomitante du GFR (octapeptide: GFR =
0,11 0,03 ml/g/min; heptapeptide: GFR = —0,08 0,07
ml/g/min; P < 0,025). Du fait que les analogues octa et heptapep-
tide étaient egalement efficaces sur le debit sanguin renal dans
cette étude, comme dans d'autres antérieures, mais que seul
l'octapeptide était efficace sur Ic glomerule isolé et pour l'aug-
mentation du GFR chez l'animal intact, nous concluons que les
récepteurs glomérulaires et vasculaires different. De plus, le
récepteur glomérulaire peut étre important dans Ia modulation de
Ia réponse fonctionnelle du glomérule a l'angiotensine.
Circumstantial but compelling evidence has sug-
gested that the vascular receptors for angiotensin in
the renal blood supply differ sufficiently from vas-
cular angiotensin receptors in other vascular beds
that agents with greater specificity for the renal
vasculature could be found [1—3]. An unstated but
implicit assumption in the investigation that fol-
lowed was that the type of receptor responsible for
the impact of angiotensin on GFR and sodium
handling within the kidney lay in either the afferent
or the efferent arteriole. In the past decade, a
number of observations based on morphologic [4—7]
and physiologic studies [8, 91 have suggested an
additional family of angiotensin receptors in the
glomerulus, receptors that could impact on renal
function through an influence on the character or
surface area of the glomerular capillary with little
influence on renal vascular resistance [8, 9].
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We have found that heptapeptide analogues of
angiotensin II (Al!) had a smaller influence on
systemic than renal vascular receptors, so that in
models in which the renin-angiotensin system was
activated and renal blood flow (RBF) reduced,
heptapeptide analogues induced a larger increase in
renal perfusion and a smaller reduction in arterial
blood pressure than did octapeptide analogues such
as saralasin [1]. To our surprise the most potent
heptapeptide analogue available, l-des-asp,8-ile
Al!, did not increase GFR as effectively as did
saralasin, despite a potentiated increase in RBF—
an observation that has also been made in another
laboratory [10, 11]. The possibility that the differen-
tial responses to the two angiotensin analogues
reflected an intraglomerular action due to a differ-
ence in the receptors within the glomerulus prompt-
ed a second line of investigation, directed toward
the glomerular receptor. Results of both studies in
vivo and in vitro are consistent with a major differ-
ence in the glomerular and vascular renal angioten-
sin receptors, which could account for the differen-
tial action of angiotensin analogues on renal perfu-
sion and filtration rate.
Methods
In vitro. The procedure used for assessing the
glomerular angiotensin receptor was modified from
that described by Sraer et al [6] and Fong and
Drummond [12]. The kidneys were obtained from
female albino rabbits (Charles River), each weigh-
ing between 2.2 and 4.5 kg and maintained on a
supplemented sodium intake by replacing tap water
with 1.0% normal saline as the drinking water for at
least 5 days prior to the study. Anesthesia was
induced with pentobarbital (50 mg/kg, i.v.). Bilater-
al nephrectomy was performed without renal artery
perfusion immediately after anesthesia was in-
duced. The outer cortex was dissected with a
surgical scalpel, rapidly cooled to 00 C on ice, and
minced with a razor blade. The resulting paste was
then processed with a phosphor bronze sieve
(#170) with an opening of 0.0035 inches (W.S.
Tyler, Inc., Ohio). The separated material was
removed from the bottom of the sieve and suspend-
ed in 40 ml of Robinson's medium (calcium, 2.5
mmoles/liter; magnesium, 1.0 mmoles/liter) for kid-
ney slices [131 by forced injection through a 22-
gauge needle. The resulting suspension was subject-
ed to centrifugation at x 1200g for 90 see, the
supernatant discarded, and the pellet resuspended
as was done previously. The washing procedure
was repeated six times. The final pellet, containing
isolated glomeruli without Bowman's capsule, was
suspended in 40 ml of the same medium, and 0.9-ml
aliquots were measured into separate test tubes.
About 60 mm was required from induction of anes-
thesia to final separation of the glomeruli.
Measurements of glomerular diameter were made
on a coded basis to avoid potential bias. The
diameters of the isolated glomeruli were measured
under a light microscope at x 100 power (Nikon)
with a television camera and video display in place
of the eye-piece ocular to facilitate measurement.
The system was equipped with a metrology unit,
which made the measurements in the focal plane of
the system (Circon Electronics, Santa Barbara,
California). This system provides a deeper focal
plane than the traditional eye-piece lens, reduces
observer fatigue, and sharply reduces the coeffi-
cient of variation in the measurements. Because
glomeruli were often not circular, measurements
were made in the widest diameter in the horizontal
plane of the microscope's stage, which was an
arbitrary function of the position of the slide. No
adjustments were made to assess the largest diame-
ter of each glomerulus. Despite this convention, the
coefficient of variation in glomerular diameter mea-
surement ranged from 5.3 to 10.7% in 11 samples,
each containing 36 to 51 glomeruli. The overall
coefficient of variation was 8.0 0.47.
Preliminary studies confirmed the observations
of Sraer et al [6] that a time-related reduction in the
size of the glomerulus occurred in response to All.
Perhaps because of decomposition of glomeruli,
glomerular diameters became extremely variable
after 60 mm. For that reason, and to allow a
complete definition of a dose-response curve and an
inhibition curve on the same family of glomeruli, we
modified the procedure by the addition of glutaral-
dehyde fixation. In four experiments, the addition
of glutaraldehyde did not vary glomerular diameter
(136.76 4.O2vs. 135.18 3.24p),andthesizeof
the glomeruli was constant for periods of up to 14
days (134.23 3.89 vs. 136.76 4.02 .t).
The relationship between the graded doses of All
and the des-asp All analogue (angiotensin III
(Alli); Bachem Inc., Marina del Ray, California)
and the change in glomerular diameter was defined:
graded doses of Al! and All!, diluted in 0.9%
sodium chloride, were added to the glomerular
suspensions to produce final concentrations of each
agent in the range of 10_13 to i0 g/liter. In a second
series of studies, we assessed the effectiveness of
one octapeptide analogue, saralasin (1-sar,8-ala
Al!, Norwich Pharmaceuticals) and two heptapep-
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tide analogues (des-asp,8-ile All (Bachem Inc.) and
des-asp,8-gly All (Norwich) at concentrations rang-
ing between l0 and 10_2 g/Iiter as antagonists of
All and Alli (10 g/liter) mediated glomerular
response. Samples were incubated for 30 mm at
room temperature and then subjected to fixation
with 1% glutaraldehyde. At least six dose-response
curves, determined from glomeruli from six differ-
ent rabbits, were used for each element of this
study.
Because of variation in the size of the glomeruli
from rabbit to rabbit, all of the dose-response data
in experiments in which antagonists have been used
have been normalized to the control (nonhormone
or drug treated) glomeruli in that experiment.
In viva. Seventeen female mongrel dogs, each
varying in weight between 15 and 25 kg, were used
in these studies. Anesthesia was induced with sodi-
um pentobarbital (30 mg/kg, i.v.). As the protocol
called for a controlled pressure elevation in the
abdominal inferior vena cava and caval pressure
was exquisitely sensitive to spontaneous move-
ments and the depth of the anesthesia, these factors
were controlled as follows: constant i.v. infusions
of sodium pentobarbital (75 mg/hr) and succinyl
choline (8.4 mg/hr) were found to be adequate to
maintain surgical anesthesia and muscular paraly-
sis; and respirations were controlled with a cuffed
endotracheal tube and a respirator pump (Harvard
Apparatus). A balloon-tipped catheter was intro-
duced into the inferior vena cava through a femoral
vein and positioned in the long thoracic segment of
the inferior vena cava using fluoroscopic control.
Pressure was measured with transducers (Statharn,
P23D6) from catheters in the aorta and abdominal
inferior vena cava. Four venous catheters were
introduced into the brachial vein through a common
sheath and used for intravenous fluid and drug
administration. Blood flow in the renal artery was
measured with an electromagnetic flow meter
(Statham) and an appropriately sized probe placed
on a proximal segment of the artery through a
retroperitoneal approach. Zero flow was obtained
by occluding the artery distal to the probe. The
probes were calibrated on the femoral artery at the
end of each experiment. The ureter was cannulated
close to the renal pelvis and the urine collected in
graduated cylinders. The RBF and the pressures in
the aorta and the inferior vena cava were recorded
on a polygraph recorder (Grass Instruments).
At the beginning of each experiment, a 20-ml/kg
i.v. infusion of either 0.9% sodium chloride or 5%
dextrose was given as a fluid load. A constant
infusion of the same solution to which mannitol
(25%) and creatinine were added was continued at
1.0 ml/min throughout the experiment.
The GFR was estimated from the clearance of
creatinine using 20-mm clearance periods and the
standard formula. After a priming dose of creatinine
(8 mg/kg) was given, a constant i.v. infusion was
given at the rate of 1.2 mg/mm; 90 mm were allowed
before commencing the first clearance period.
Blood was taken at the midpoint of each clearance
period to measure creatinine.
After two consecutive control clearance periods,
the balloon in the thoracic inferior vena cava was
gradually inflated until pressure in the abdominal
inferior vena cava reached a level of between 7 and
10 mm Hg, and this pressure was maintained by
adjustments of a micrometer syringe attached to the
catheter. After a 30-mm period for stabilization, an
additional clearance period was obtained. In 10
dogs, saralasin was given as an i.v. infusion in log-
dose increments in the dose range of 300 to 3000
ng/kg/min. A clearance period was obtained during
infusion of saralasin at the dose that induced the
greatest increase in RBF. Of the 10 dogs, 2 have
been excluded because a clearance period was not
obtained during a RBF increase. One responded to
caval occlusion with a marked fall in arterial pres-
sure and a further decrease in pressure and a
concomitant fall in RBF with the use of saralasin.
The other initially responded to saralasin with an
increase in RBF but progressive parallel falls in
both arterial pressure and RBF occurred during the
clearance period.
In a further 7 dogs, the heptapeptide analogue
des-asp,8-ile All was given instead of saralasin in
the dose range of 100 to 3000 ng/kg/min, and a
clearance period was obtained at the dose that
produced the maximum increase in RBF. None
developed hypotension.
Mean values have been presented with a standard
error of the mean as the index of dispersion. The
null hypothesis was tested by the Student's t test or
nonparametric tests such as Chi square, and the
Wilcoxon Rank sum test, when applicable, and
rejected when a P value of less than 0.05 was
obtained.
Results
In vitro. All and AIII (Fig.!) induced identical
changes in the diameter of isolated glomeruli over a
wide dose range. Inhibition, induced by the ana-
logues, of the glomerular response to angiotensin
has been expressed as percent inhibition, from the
690 Renal angiotensin receptors
formula (C — R)!C (100), where C is control glomer-
ular response to a standard dose of All or Aill (l0
g/liter) and R is response in the presence of an
antagonist (Fig. 2, A and B). The octapeptide was
equally effective at blocking glomerular responses
induced by either All or Alil. Both heptapeptide
analogues failed to block glomerular changes in-
duced by either agonist.
In vivo. Data for these studies are summarized in
Table 1. Partial occlusion of the thoracic inferior
vena cava in 15 dogs resulted in decreases in RBF
(34.8%), GFR (29.0%), and arterial pressure
(13.0%). Intravenous infusions of graded doses of
saralasin and des-asp,8-ile All during caval occlu-
sion increased RBF, 0.41 0.11 and 0.62 0.11
mug/mm, respectively, with the optimal dose in
individual animals varying between 300 and 3000
nglkglmin. Maximal analogue-induced increases in
RBF were associated with a significant increase in
GFR when saralasin was used (LGFR = 0.11
0.03 mug/mm), but GFR was not changed by des-
asp,8-ile All (zGFR = —0.08 0.07 ml/g/min) (P
<0.025).
Discussion
The finding that both octapeptide and heptapep-
tide analogues modified renal responses to angio-
tensin [1, 3, 10, 11, 14], but that only the octapep-
tide was effective in isolated glomeruli, suggests
that angiotensin receptors in glomeruli differ from
those in the renal vasculature. Results in the caval
dog support this suggestion: octapeptide and hepta-
peptide analogues increased RBF, but only the
octapeptide induced a concomitant increase in
GFR.
Use of the heptapeptide analogue in the caval dog
model was associated with a better maintained
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Fig. 1. Identical decreases in the diameter of isolated rabbit
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Fig. 2. A Reduction in glomerular diameter by an octapeptide
analogue (1-sar,8-ala All). Percent inhibition of All was calcu-
lated from the formula (C — R)IC(100), where C is glomerular
response to All (1O gfliter) and R is response in presence of
analogue, Two heptapeptide analogues failed to inhibit the
glomerular response to All. B Same asforA except All! (lOs gi
liter) was the agonist.
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Table 1. Responses to an octapeptide and a heptapeptide analogue during caval occlusiona
Control Caval Analogue
Saralasin
Blood pressure, mm Hg 132.3 4.5 116.9 7.3 103.1 6.7 NS
Renal blood flow, mug/mm 4.05 0.24 2.64 0•19d 3.05
GFR, mug/mm 1.02 0.10 0.66 0.07c 0.77 O.60c
des-Asp, 8-lie All
Blood pressure, mm Hg









GFR, mi/glmmn 0.84 0.08 0.67 0.09 0.60 0.03
a Values are the means SEM.
b P < 0.05.
C P < 0.02.
d P <0.01.
NS.
both should have favored glomerular filtration.
There are several possible explanations for the
failure of the heptapeptide to increase GFR. The
response may have been limited by the intrinsic
activity of the heptapeptide, but this is inconsistent
with the finding that the heptapeptide induced a
greater increase in RBF than did the octapeptide.
Alternatively, the heptapeptide may have induced
relatively greater vasodilatation in postglomerular
than preglomerular arterioles compared with the
octapeptide analogue, possibly reflecting differ-
ences in afferent and efferent arteriolar angiotensin
receptors. Steiner and Blantz, however, have re-
cently documented by micropuncture a direct influ-
ence of saralasin on the glomerular ultrafiltration
coefficient and the efferent arteriole, with no appar-
ent effect on the afferent arteriole at the saralasin
dose they used [15]. They did not use heptapeptide
analogues. Hence, present in vivo data are most
consistent with the in vitro data that suggest that the
failure of the heptapeptide analogue to increase
GFR was due to its failure to block a direct action of
angiotensin on the glomerulus.
What alternative to differing receptors could ac-
count for our findings? The only plausible alterna-
tive would be differing rates of degradation of the
heptapeptides. We have assessed and ruled out that
possibility for the renal vasculature in an earlier
study [16]. Such a difference should have expressed
itself in this study in a difference in the potency of
All and Alli as agonists in vitro: such a difference
did not exist, making it unlikely that degradation
accounts for the failure of the heptapeptide ana-
logues to block in vitro.
If differing renal receptors for angiotensin indeed
exist and account for the failure of the heptapeptide
analogue to increase glomerular filtration, where
could they be located? The efferent arteriole and the
glomerulus are the two candidates. As indicated
earlier, preferential efferent arteriolar dilatation in-
duced by the heptapeptide analogue would account
for the in vivo findings—but would make it neces-
sary to posit three differing angiotensin receptors,
in the afferent arteriole, in the efferent arteriole, and
in the glomerulus. On the other hand, a difference in
glomerular and arteriolar receptors can account for
all of the observed differences with a more parsimo-
nious hypothesis, requiring only two receptors. In
the absence of more direct information on the
arteriolar receptors, however, conclusions remain
speculative.
Recent studies in intact animals and isolated
glomeruli have demonstrated a glomerular angio-
tensin receptor in the mesangial cells. Radiolabeled
All is bound primarily to mesangial cells and to a
lesser extent to the glomerular basement membrane
[5—7, 17]. Analogues of All and unlabeled Al, All,
and Alil compete for binding sites [5, 6]. Further-
more, graded concentrations of All, within the
physiologic range, have been shown to produce
graded decreases in the diameter of isolated glomer-
uli [6], and this has been confirmed in the present
study and extended to show identical glomerular
responses to both All and AIlI. Our modifications
in the method for assessing isolated glomerular
response facilitated our study. Glutaraldehyde fix-
ation made it possible to produce full dose-response
curves for the agonists and the antagonists from one
population of glomeruli without the time restraint
imposed by spontaneous degeneration of the gb-
mcmli after harvesting [6]. The method used for
measuring glomerular diameters had the advantage
of reducing operator fatigue so that a larger popula-
tion of glomeruli could be measured at each dose
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level, resulting in good reproducibility, as indicated
by the low coefficient of variation. Because angio-
tensin caused the glomerulus to shrink, some con-
tractile function within the glomerulus must be
involved, and the mesangium represents the only
candidate. A direct action of angiotensin, resulting
in contraction of mesangial cells, has been demon-
strated in vitro [18].
The mesangium is strategically located to modify
blood flow and pressure within glomerular capillary
loops. Morphologic studies of the glomerulus with
the scanning electron microscope have demonstrat-
ed collapse and tortuosity of individual capillary
loops in response to All, with the number of loops
involved and the magnitude of the collapse a func-
tion of dose [4]. Hence, angiotensin cannot only
decrease capillary blood flow but can also decrease
the surface area for ultrafiltration. The demonstra-
tion of angiotensin binding sites on the glomerular
basement membrane raises the further possibility
that angiotensin may modify glomerular filtration
through changes in the ultrafiltration coefficient by
a direct action on the basement membrane [171. In
physiologic models, the ultrafiltration coefficient
was decreased by i.v. infusion of All in rats which
were volume expanded to permit measurement of
ultrafiltration coefficient [8, 9]: reduction in glomer-
ular blood flow tended to be offset by an increase in
pressure change across the glomerulus.
In the caval dog model, the renal response to the
analogues may have been limited by the intrinsic,
angiotensin-like activity of the agents and the de-
crease in arterial pressure that accompanied their
i.v. administration. Others have shown that the
sympathetic nervous system is also involved in the
renal response to caval occlusion [19, 20], but the
relative roles of the renin-angiotensin system and
the sympathetic nervous system have not been
defined. Angiotensin probably modifies renal perfu-
sion and GFR by direct actions on pre- and post-
glomerular arterioles and the glomerulus [4, 6, 8, 9,
17].
We have previously demonstrated that heptapep-
tide analogues have greater specificity for the renal
than they do for the peripheral vasculature [1, 31,
and we therefore assumed that such analogues
would have a more favorable influence on renal
excretory functions. The failure of the heptapeptide
analogue to influence glomerular angiotensin recep-
tors, and to induce an increase in GFR in the intact
animal, suggests that an alternative approach to
finding a renal-specific angiotensin antagonist will
have to be sought. The isolated glomerular model
may prove to be an important tool in the search for
angiotensin antagonists that improve renal function.
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